Company Filing History:
Years Active: 1976-1979
Title: Max Brugger - Pioneer in Hypocalcaemic Peptide Innovations
Introduction
Max Brugger, an inventive mind hailing from Birsfelden, Switzerland, has made significant contributions to the field of biochemistry through his pioneering work in the development of hypocalcaemic peptides. With a total of four patents to his name, Brugger stands as a noteworthy figure in the scientific community, particularly for his advancements in peptide synthesis and their applications in medical therapies.
Latest Patents
Among Max Brugger's latest contributions is his patent focused on "Peptides and process for their manufacture." This innovative work details a new set of hypocalcaemically active peptides characterized by specific chemical formulas, which involve modifications of asparagine and glutamic acid radicals. These peptides, especially those comprising identical sequences joined in an anti-parallel formation through cysteine radicals, have potential applications as hypocalcaemic agents. His other notable patent is for "Hypocalcaemic peptides and processes for their manufacture," which outlines a synthetic hypocalcaemic dotriacontapeptide, further emphasizing his commitment to advancing peptide technology.
Career Highlights
Max Brugger has established himself within the prestigious Ciba-Geigy Corporation, where he has continued to innovate and push the boundaries of peptide research. His work is recognized not only for its scientific merit but also for its practicality in addressing health-related issues, particularly concerning calcium regulation in the human body.
Collaborations
Throughout his career, Brugger has worked alongside esteemed colleagues including Werner Rittel and Bernhard Riniker. These collaborations have been instrumental in furthering research initiatives and enhancing the developmental processes of groundbreaking therapeutic peptides.
Conclusion
In summary, Max Brugger is a distinguished inventor whose contributions to the field of hypocalcaemic peptides are notable and impactful. His dedication to research at Ciba-Geigy Corporation, along with the collaborative efforts with his peers, has positioned him as a leading figure in the scientific community. The innovations he has brought forth are set to pave the way for new treatments and enhance the understanding of peptide functionality in medical science.